ABL1 and acute lymphoblastic leukemia: Shin Sy et al.19 reported a B-ALL patient with e1a3 variant who received imatinib combined with chemotherapy but failed to achieve complete remission, and subsequently developed the E255v mutation in the ABL kinase region at 12 months and died of multiple organ failure at 16 months.